Transplant characteristics
. | Number . |
|---|---|
| G-CSF-mobilized PBSCs | 18 |
| Bone marrow | 3 |
| Donor type | |
| Related HLA-matched | 18 |
| Related HLA 1-Ag-mismatched | 1 |
| Unrelated HLA-matched | 2 |
| Conditioning regimens* | |
| TBI 200; Fludara 90 mg/m2 | 3 |
| TBI 200; Fludara 90 mg/m2; ATG | 2 |
| TBI 450; Fludara 120 mg/m2; alemtuzumab 30 mg | 1 |
| Fludara 150 mg/sqm; Mel 140 mg/m2 | 6 |
| Fludara 150 mg/sqm; Mel 180 mg/m2; ATG | 1 |
| Thiotepa 10 mg/kg; Cy 100 mg/kg | 7 |
| Thiotepa 10 mg/kg; Fludara 125 mg/m2 | 1 |
. | Number . |
|---|---|
| G-CSF-mobilized PBSCs | 18 |
| Bone marrow | 3 |
| Donor type | |
| Related HLA-matched | 18 |
| Related HLA 1-Ag-mismatched | 1 |
| Unrelated HLA-matched | 2 |
| Conditioning regimens* | |
| TBI 200; Fludara 90 mg/m2 | 3 |
| TBI 200; Fludara 90 mg/m2; ATG | 2 |
| TBI 450; Fludara 120 mg/m2; alemtuzumab 30 mg | 1 |
| Fludara 150 mg/sqm; Mel 140 mg/m2 | 6 |
| Fludara 150 mg/sqm; Mel 180 mg/m2; ATG | 1 |
| Thiotepa 10 mg/kg; Cy 100 mg/kg | 7 |
| Thiotepa 10 mg/kg; Fludara 125 mg/m2 | 1 |
Fludara indicates fludarabine; ATG, antithymocyte globulin; Mel, melphalan; and Cy, cyclophosphamide.
Described in “Patients, materials, and methods” and in Devine et al,18 Grosskreutz et al,20 Alessandrino et al,21 and Bacigalupo et al22